首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1729413

日本醫藥市場報告（依處方類型、治療類別和地區）2025-2033

Japan Pharmaceutical Market Report by Prescription Type, Therapeutic Category, and Region 2025-2033

出版日期: 2025年05月01日 | 出版商:

IMARC | 英文 119 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本醫藥市場規模達822.7億美元。展望未來， IMARC Group預計到2033年市場規模將達到1,019億美元，2025-2033年期間的成長率（CAGR）為2.57%。眾多的治療方法和創新療法以及對藥物研發活動不斷增加的投資，主要促進了市場的成長。

製藥業代表科學、創新和治療護理的融合，致力於促進全球健康。該行業的核心是負責研究、開發、生產和分銷用於預防、控制或治療多種醫療狀況和疾病的藥物。從救命的疫苗到日常止痛藥，藥品在提高生活品質和延長壽命方面發揮著不可或缺的作用。藥物開發過程是一個複雜而嚴格的過程，需要進行大量的研究、臨床試驗和監管部門的批准，以確保藥物的療效和對病人的安全。除了有形的藥物之外，製藥業的價值還在於其對新治療前沿、突破性治療方法和可能重新定義醫學範式的創新的不懈追求。隨著健康挑戰的不斷演變，該行業的重要性（以其改善人類健康的承諾為基礎）仍然至關重要。

日本醫藥市場趨勢：

生物製藥和精準醫療的投資不斷增加

生物製藥和精準醫療投資的不斷成長正在迅速改變日本製藥業的動態。生物製藥，例如生物製劑和生物學名藥，由於在治療癌症或自體免疫疾病等慢性疾病方面的獨創性而越來越受到青睞。隨著基因組學和個人化醫療的進步，治療重點正轉向針對個人基因特徵的客製化治療。因此，日本主要製藥商正在與海外公司和研究中心建立合資企業來培育這項技術。透過對個人化治療的加強關注，為以前難以解決的疾病提供有針對性的解決方案，進一步擴大了醫藥市場的範圍。

人口老化和醫療保健需求成長

人口快速老化是推動醫藥市場成長的關鍵因素。這種人口結構的變化增加了與年齡相關的疾病和心血管疾病、糖尿病和阿茲海默症等慢性疾病的藥物的整體需求。此外，隨著人們的注意力轉向管理慢性病和改善老年人的生活品質，隨著醫療保健系統的改善，對有效治療和藥物的需求也在成長。此外，藥廠正在加大老年藥物的研發力度，開發專門針對老年護理的綜合藥物配方。這一人口趨勢吸引了國內外公司的大量投資，為日本醫藥市場的佔有率做出了貢獻。

藥物開發和製造技術的不斷進步

人工智慧 (AI)、機器學習 (ML) 和流程自動化等尖端技術的持續創新，特別是它們融入臨床前研究和藥物製造中，正在支持市場的成長。臨床試驗和藥物安全監測中的數據驅動方法正在幫助製藥公司更快地將新療法推向市場。穿戴式裝置和數位健康工具（包括遠距醫療）也在促進更好的藥物依從性和更個人化的治療計畫。此外，生物加工方面的創新和機器人技術在藥品生產中的應用正在提高效率，而先進的分析技術則支援在整個藥物開發生命週期中做出更好的決策。

日本醫藥市場細分：

處方類型洞察：

處方藥
- 品牌
- 泛型
非處方藥

治療類別洞察：

抗過敏藥
血液和造血器官
心血管系統
皮膚
泌尿生殖系統
呼吸系統
感覺器官
其他

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀表板和公司評估象限等競爭分析。此外，也提供了所有主要公司的詳細資料。

日本醫藥市場新聞：

2024 年 10 月 1 日，Nxera Pharma Co., Ltd. 與 Shionogi & Co., Ltd. 就 QUVIVIQ(TM)（daridorexant 25 和 50 毫克）在日本的分銷和銷售達成合作協議。 QUVIVIQ 是由 Idorsia Pharmaceuticals Ltd 發現的一種新型雙食慾素受體拮抗劑，已獲得日本厚生勞動省（「MHLW」）批准用於治療成年失眠患者。

本報告回答的關鍵問題：

日本醫藥市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本醫藥市場有何影響？
日本藥品市場如何依處方類型分類？
日本醫藥市場如何按治療類別分類？
日本醫藥市場的價值鏈分為哪些階段？
日本製藥業的主要促進因素和挑戰是什麼？
日本醫藥市場的結構是怎麼樣的？主要參與者是誰？
日本醫藥市場的競爭程度如何？

本報告回答的關鍵問題：

日本醫藥市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本醫藥市場有何影響？
日本藥品市場如何依處方類型分類？
日本醫藥市場如何按治療類別分類？
日本醫藥市場的價值鏈分為哪些階段？
日本製藥業的主要促進因素和挑戰是什麼？
日本醫藥市場的結構是怎麼樣的？主要參與者是誰？
日本醫藥市場的競爭程度如何？

Japan pharmaceutical market size reached USD 82.27 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 101.90 Billion by 2033, exhibiting a growth rate (CAGR) of 2.57% during 2025-2033. Numerous treatments and innovative therapies and the increasing investments in the R&D activities for developing medicines, are primarily augmenting the market growth.

The pharmaceutical industry represents a confluence of science, innovation, and therapeutic care, dedicated to advancing global health. At its core, this sector is responsible for the research, development, production, and distribution of medications designed to prevent, manage, or cure a plethora of medical conditions and diseases. Spanning from life-saving vaccines to everyday pain relievers, pharmaceuticals play an integral role in enhancing the quality of life and increasing life expectancy. The journey of drug development is a complex and rigorous process, necessitating extensive research, clinical trials, and regulatory approvals to ensure both efficacy and safety for patients. Beyond the tangible medications, the pharmaceutical industry's value also lies in its relentless pursuit of new therapeutic frontiers, breakthrough treatments, and innovations that have the potential to redefine medical paradigms. As health challenges continue to evolve, the importance of this industry, underpinned by its commitment to bettering human health, remains paramount.

Japan Pharmaceutical Market Trends:

Growing investments in biopharmaceuticals and precision medicine

Growing investments in biopharmaceuticals and precision medicines is rapidly transforming the dynamics of the pharmaceutical industry in Japan. Biopharmaceuticals, such as biologics, and biosimilars are gaining more preference due to originality in treatment of chronic diseases, such as cancer or autoimmune diseases. With advancements in genomics and personalized medicine, the focus is shifting towards treatments tailored to individual genetic profiles. As a result, major Japanese drug manufacturers are engaging in joint ventures involving overseas companies and research centers to foster this technology. An enhanced focus on individualized treatments is further extending the range of the pharmaceutical market by offering targeted solutions to previously hard-to-solve diseases.

Aging Population and Rising Healthcare Demand

The rapidly aging population is a key factor propelling growth in the pharmaceutical market. This demographic shift is increasing the overall demand for medications targeting age-related diseases and chronic conditions such as cardiovascular diseases, diabetes, and Alzheimer's. Also, with shifting focus to managing chronic illnesses and improving the quality of life for senior citizens, the demand for effective treatments and medications is growing with the improving healthcare system. Furthermore, pharmaceutical companies are expanding their R&D efforts in geriatric medicines, developing comprehensive drug formulations specifically designed for elderly care. This demographic trend is attracting heavy investments from both local and international firms, contributing to the Japan pharmaceutical market share.

Continual technological advancements in drug development and manufacturing

Ongoing innovations in cutting-edge advancements, such as artificial intelligence (AI), machine learning (ML), and process automation, particularly as they are integrated into both preclinical research and drug manufacturing, are supporting the growth of the market. Data-driven methods in clinical trials and drug safety monitoring are helping pharmaceutical companies bring new therapies to market faster. Wearable devices and digital health tools, including telemedicine are also fostering better drug adherence and more personalized treatment plans. Additionally, innovations in bioprocessing and the use of robotics in pharmaceutical production are improving efficiency, while advanced analytics support better decision-making throughout the drug development lifecycle.

Japan Pharmaceutical Market Segmentation:

Prescription Type Insights:

Prescription Drugs
- Branded
- Generics
OTC Drugs

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Japan Pharmaceutical Market News:

On 1st October 2024, Nxera Pharma Co., Ltd. formed a partnership agreement with Shionogi & Co., Ltd. regarding the distribution and sales for QUVIVIQ(TM) (daridorexant 25 and 50 mg) in Japan. QUVIVIQ is a novel dual orexin receptor antagonist, discovered by Idorsia Pharmaceuticals Ltd, that was approved by the ministry of health, labour, and welfare of Japan ("MHLW") for the treatment of adult patients with insomnia.

Key Questions Answered in This Report:

How has the Japan pharmaceutical market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan pharmaceutical market?
What is the breakup of the Japan pharmaceutical market on the basis of prescription type?
What is the breakup of the Japan pharmaceutical market on the basis of therapeutic category?
What are the various stages in the value chain of the Japan pharmaceutical market?
What are the key driving factors and challenges in the Japan pharmaceutical?
What is the structure of the Japan pharmaceutical market and who are the key players?
What is the degree of competition in the Japan pharmaceutical market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pharmaceutical Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Pharmaceutical Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Pharmaceutical Market - Breakup by Prescription Type

6.1 Prescription Drugs
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Segmentation
  - 6.1.3.1 Branded
  - 6.1.3.2 Generics
- 6.1.4 Market Forecast (2025-2033)
6.2 OTC Drugs
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)

7 Japan Pharmaceutical Market - Breakup by Therapeutic Category

7.1 Antiallergics
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Blood and Blood Forming Organs
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Cardiovascular System
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Dermatological
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Genito Urinary System
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Respiratory System
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2019-2024)
- 7.6.3 Market Forecast (2025-2033)
7.7 Sensory Organs
- 7.7.1 Overview
- 7.7.2 Historical and Current Market Trends (2019-2024)
- 7.7.3 Market Forecast (2025-2033)
7.8 Others
- 7.8.1 Historical and Current Market Trends (2019-2024)
- 7.8.2 Market Forecast (2025-2033)

8 Japan Pharmaceutical Market - Competitive Landscape

8.1 Overview
8.2 Market Structure
8.3 Market Player Positioning
8.4 Top Winning Strategies
8.5 Competitive Dashboard
8.6 Company Evaluation Quadrant

9 Profiles of Key Players

9.1 Company A
- 9.1.1 Business Overview
- 9.1.2 Product Portfolio
- 9.1.3 Business Strategies
- 9.1.4 SWOT Analysis
- 9.1.5 Major News and Events
9.2 Company B
- 9.2.1 Business Overview
- 9.2.2 Product Portfolio
- 9.2.3 Business Strategies
- 9.2.4 SWOT Analysis
- 9.2.5 Major News and Events
9.3 Company C
- 9.3.1 Business Overview
- 9.3.2 Product Portfolio
- 9.3.3 Business Strategies
- 9.3.4 SWOT Analysis
- 9.3.5 Major News and Events
9.4 Company D
- 9.4.1 Business Overview
- 9.4.2 Product Portfolio
- 9.4.3 Business Strategies
- 9.4.4 SWOT Analysis
- 9.4.5 Major News and Events
9.5 Company E
- 9.5.1 Business Overview
- 9.5.2 Product Portfolio
- 9.5.3 Business Strategies
- 9.5.4 SWOT Analysis
- 9.5.5 Major News and Events

10 Japan Pharmaceutical Market - Industry Analysis

10.1 Drivers, Restraints and Opportunities
- 10.1.1 Overview
- 10.1.2 Drivers
- 10.1.3 Restraints
- 10.1.4 Opportunities
10.2 Porters Five Forces Analysis
- 10.2.1 Overview
- 10.2.2 Bargaining Power of Buyers
- 10.2.3 Bargaining Power of Suppliers
- 10.2.4 Degree of Competition
- 10.2.5 Threat of New Entrants
- 10.2.6 Threat of Substitutes
10.3 Value Chain Analysis